ACADIA second-quarter net loss decreases to $4.3 million ACADIA Pharmaceuticals Inc http://suhagracipla.org/ . , a biopharmaceutical company making use of innovative technology to fuel drug discovery and scientific development of novel treatments for central nervous system disorders, today reported its unaudited financial outcomes for the second quarter ended June 30, 2010.3 million, or $0.11 per common talk about, for the next quarter of 2010 compared to a net loss of $12.7 million, or $0.34 per common talk about, for the second quarter of 2009. For the half a year ended June 30, 2010, ACADIA reported a net loss of $9.8 million, or $0.25 per common share, compared to a net loss of $27.7 million, or $0.75 per common share, for the comparable amount of 2009.
Gain access to receives $6.7M NIH Clinical and Translational Science Award Access Community Health Network has received a $6.7 million Clinical and Translational Technology Award grant from the National Institutes of Health to construct a community-based research center. The goal of the center’s research is to engage the city and reduce racial and ethnic disparities in health care. Through its Roadmap Initiative NIH intends to transform how analysis is carried out by encouraging researchers to connect with communities. ACCESS is among only three non-academic organizations to receive among NIH’s community-based study grants. Related StoriesSmartphone checks blood for parasitic diseasePreventing falls in treatment homes: an interview with Professor Pip LoganGreater evidence-based help needed for depressed workers – New report from The Work Foundation’When most people think about research they envision university researchers in lab coats looking through microscopes,’ stated Donna Thompson, CEO of ACCESS, the nation’s largest network of federally-qualified wellness centers.